8-K: Milestone Pharmaceuticals Reports Q1 2025 Financial Results and Provides Regulatory Update on CARDAMYST

Milestone Pharmaceuticals announced its Q1 2025 financial results, alongside an update on regulatory efforts to address issues raised by the FDA regarding its CARDAMYST application.

Summary

• Milestone Pharmaceuticals reported its financial results for the first quarter ended March 31, 2025.
• The company is working to resolve issues raised by the FDA in the Complete Response Letter (CRL) for CARDAMYST, a treatment for paroxysmal supraventricular tachycardia (PSVT).
• Milestone has requested a Type A meeting with the FDA to discuss Chemistry, Manufacturing, and Controls (CMC) issues outlined in the CRL.
• A new patent was issued by the USPTO for etripamil nasal spray, potentially extending intellectual property protection in the U.S. until July 2042.
• Milestone finalized the Phase 3 study protocol for etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR) but is pausing enrollment to focus on resolving the CARDAMYST CRL.
• As of March 31, 2025, Milestone had $56.0 million in cash, cash equivalents, and short-term investments, compared to $69.7 million at the end of 2024.
• There was no revenue for the first quarter of 2025.
• The net loss for the first quarter of 2025 was $20.8 million, compared to a net loss of $10.4 million for the same period in 2024.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the CRL received from the FDA, which introduces uncertainty and delays. However, the company is taking steps to address the issues, and there are some positive developments, such as the new patent and survey results.

Positives

• A new patent was issued for etripamil nasal spray, potentially extending intellectual property protection until July 2042.
• CARDAMYST was selected by 40% of respondents in an independent survey as the new drug expected to make the biggest difference in patient health.
• Milestone has finalized the Phase 3 study protocol for etripamil in AFib-RVR following FDA review and concurrence.

Negatives

• Milestone received a Complete Response Letter (CRL) from the FDA regarding its NDA for CARDAMYST for PSVT.
• The company is pausing initiation of enrollment in the Phase 3 study of etripamil for AFib-RVR to prioritize resolving the CARDAMYST CRL.
• The net loss for the first quarter of 2025 was $20.8 million, compared to a net loss of $10.4 million for the same period in 2024.

Risks

• The company faces the risk of not being able to adequately address the issues raised in the CRL from the FDA.
• There is a risk that the FDA may not approve the NDA for etripamil.
• The company's ability to launch CARDAMYST is dependent on FDA approval.
• The company's financial results are subject to risks related to the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate.

Future Outlook

The company intends to engage with the FDA to address the CMC-related issues raised in the CRL for CARDAMYST and remains committed to the potential of CARDAMYST. Milestone has temporarily paused the ramping of operational expenditures related to launch, but will maintain the capability to launch quickly, pending approval of CARDAMYST by the FDA.

Management Comments

• Our immediate priority is to engage with the U.S. FDA in order to address the CMC-related issues raised in the CRL received for CARDAMYST as a treatment for PSVT, said Joe Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals.
• We are confident we can work with the FDA to fully respond to the CRL and remain committed to the potential of CARDAMYST.
• If approved, it will be the first and only self-administered therapy for the rapid termination of episodes of PSVT.

Industry Context

Milestone Pharmaceuticals is focused on developing and commercializing innovative cardiovascular solutions. The CRL for CARDAMYST highlights the regulatory challenges in bringing novel therapies to market, particularly concerning manufacturing and quality control. The company's focus on self-administered therapies aligns with the trend towards patient-centric healthcare and on-demand treatment options.

Comparison to Industry Standards

• It is difficult to compare Milestone's results directly to industry standards without knowing the specific stage of development and the competitive landscape for PSVT and AFib-RVR treatments.
• Companies like BioMarin Pharmaceutical Inc. and Sarepta Therapeutics, Inc. have faced similar regulatory hurdles in the past, including CRLs related to manufacturing issues.
• The successful resolution of these issues and eventual approval of their therapies demonstrates the potential for Milestone to overcome the challenges with CARDAMYST.
• The potential market for self-administered PSVT and AFib-RVR treatments is significant, as it addresses an unmet need for patients who experience frequent and symptomatic episodes.

Stakeholder Impact

• Shareholders may be concerned about the CRL and the potential impact on the company's stock price.
• Patients with PSVT may experience a delay in the availability of CARDAMYST as a treatment option.
• Employees may face uncertainty related to the company's future plans and potential restructuring.

Next Steps

• Milestone will request a Type A meeting with the FDA to discuss the issues raised in the CRL for CARDAMYST.
• The company will work to address the CMC-related issues outlined in the CRL.
• Milestone will determine the appropriate timing for resuming enrollment in the Phase 3 study of etripamil for AFib-RVR.

Key Dates

Keywords

Milestone Pharmaceuticals, CARDAMYST, Etripamil, PSVT, AFib-RVR, FDA, CRL, Patent, Financial Results, Regulatory Update